Molecular docking study of lignanamides from Cannabis sativa against P-glycoprotein.

In Silico Pharmacology Pub Date : 2021-01-03 eCollection Date: 2021-01-01 DOI:10.1007/s40203-020-00066-7
Farnoosh Kazemi, Isaac Karimi, Namdar Yousofvand
{"title":"Molecular docking study of lignanamides from <i>Cannabis sativa</i> against P-glycoprotein.","authors":"Farnoosh Kazemi,&nbsp;Isaac Karimi,&nbsp;Namdar Yousofvand","doi":"10.1007/s40203-020-00066-7","DOIUrl":null,"url":null,"abstract":"<p><p>P-glycoprotein (P-gp), which was first identified in cancer cells, is an ATP-dependent efflux transporter that expels a wide variety of cytotoxic compounds out of cells. This transporter can decrease the bioavailability of therapeutic drugs by preventing their sufficient intracellular accumulation. Over expression of P-gp in cancer cells lead to multidrug resistance (MDR) phenotype that is one of the main reasons for the failure of chemotherapy. Hence, P-gp inhibition is a favorable method to reverse MDR. In this study, the lignanamides from <i>Cannabis sativa</i> were docked against P-gp to recognize potential binding affinities of these phytochemicals. Tariquidar and zosuquidar, two well-known P-gp inhibitors, were selected as the control ligands. It was observed that cannabisin M and cannabisin N exhibited higher binding affinities (- 10.2 kcal/mol) to drug-binding pocket of P-gp when compared with tariquidar and zosuquidar that showed binding affinities of - 10.1 and - 9.6 kcal/mol, respectively. Based on these findings, cannabisin M and cannabisin N could be good drug candidates against P-gp.</p>","PeriodicalId":13380,"journal":{"name":"In Silico Pharmacology","volume":" ","pages":"6"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40203-020-00066-7","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In Silico Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40203-020-00066-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

P-glycoprotein (P-gp), which was first identified in cancer cells, is an ATP-dependent efflux transporter that expels a wide variety of cytotoxic compounds out of cells. This transporter can decrease the bioavailability of therapeutic drugs by preventing their sufficient intracellular accumulation. Over expression of P-gp in cancer cells lead to multidrug resistance (MDR) phenotype that is one of the main reasons for the failure of chemotherapy. Hence, P-gp inhibition is a favorable method to reverse MDR. In this study, the lignanamides from Cannabis sativa were docked against P-gp to recognize potential binding affinities of these phytochemicals. Tariquidar and zosuquidar, two well-known P-gp inhibitors, were selected as the control ligands. It was observed that cannabisin M and cannabisin N exhibited higher binding affinities (- 10.2 kcal/mol) to drug-binding pocket of P-gp when compared with tariquidar and zosuquidar that showed binding affinities of - 10.1 and - 9.6 kcal/mol, respectively. Based on these findings, cannabisin M and cannabisin N could be good drug candidates against P-gp.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
大麻木质素胺对p -糖蛋白的分子对接研究。
p -糖蛋白(P-gp)是一种atp依赖的外排转运蛋白,可将多种细胞毒性化合物排出细胞外。这种转运体可以通过阻止治疗药物在细胞内的充分积累而降低治疗药物的生物利用度。P-gp在癌细胞中的过度表达导致多药耐药(MDR)表型,是化疗失败的主要原因之一。因此,P-gp抑制是逆转MDR的一种有利方法。在这项研究中,从大麻中提取的木脂素胺与P-gp对接,以识别这些植物化学物质的潜在结合亲和力。选择两种著名的P-gp抑制剂Tariquidar和zosuquiar作为对照配体。结果表明,大麻素M和大麻素N对P-gp药物结合袋的结合亲和力(- 10.2 kcal/mol)高于tariquidar和zosuquiar,前者的结合亲和力分别为- 10.1和- 9.6 kcal/mol。基于这些发现,大麻素M和大麻素N可能是抗P-gp的良好候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Predicting phase-I metabolism of piceatannol: an in silico study Exploring isoindolin-1-ones as potential CDK7 inhibitors using cheminformatic tools Investigation of alpha amylase inhibitors from Bidens pilosa L. by in silico and in vitro studies Network pharmacology reveals the potential of Dolastatin 16 as a diabetic wound healing agent. RND pump inhibition: in-silico and in-vitro study by Eugenol on clinical strain of E. coli and P. aeruginosa.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1